Immunotherapy approaches targeting regulatory T-cells

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 997-1003

  Onishi, Hideya ^a   Morisaki, Takashi ^b   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Fukuoka General Cancer Clinic   (Japan)

Author keywords

Cd4+ t cell; Dendritic cells; Immunotherapy; Regulatory t cells; Review; Treg

Indexed keywords

B7 ANTIGEN; BASILIXIMAB; CANCER VACCINE; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DASATINIB; DENILEUKIN DIFTITOX; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOTOXIN LMB2; IPILIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 0X40; PADGEM PROTEIN; TACROLIMUS; TICILIMUMAB; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; COLON CANCER; EXOSOME; GAMMA DELTA T LYMPHOCYTE; HAIRY CELL LEUKEMIA; HUMAN; INOPERABLE CANCER; MELANOMA; NATURAL KILLER T CELL; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STOMACH CANCER; THYMUS;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84858771966     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR and Vignali DA: The development and functuin of regulatory T cells. Cell Mol Life Sci 66: 2603-2622, 2009.
2. + regulatory T-cells for immunologic self-tolerance and negative control of immune response. Annu Rev Immunol 22: 531-562, 2004.
3. Asano M, Toda M, Sakaguchi N and Sakaguchi S: Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184: 387-396, 1996. (Pubitemid 26324092)
4. + regulatory T-cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116: 2423-2433, 2006.
5. + T-cells in the periphery. Nat Rev Immunol 7: 231-237, 2007.
6. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, Barthlott T, Stockinger B, Wraith DC and O'Garra A: IL-10-secreting regulatory T cells do not express FOXP3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T-cells. J Immunol 172: 5986-5993, 2004. (Pubitemid 38621199)
7. Weiner HL: Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182: 207-214, 2001.
8. + Tregss and NKT cells: regulators regulating regulators. Trends Immunol 27: 322-327, 2006.
9. Taniguchi M, Harada M, Kojo S, Nakayama T and Wakao H: The regulatory role of Valpha 14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21: 483-513, 2003. (Pubitemid 37174539)
10. Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900, 2005.
11. Liu Z, Tugulea R, Cortesini R and Suciu-Foca N: Specific suppression of T helper alloreactivity by allo-MHC classI-restricted CD8+CD28- T-cells. Int Immunol 10: 775-783, 1998. (Pubitemid 28279480)
12. Myers L, Croft M, Kwon BS, Mittler RS and Vella AT: Peptide-specific CD8 T-regsulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol 174: 7625-7632, 2005. (Pubitemid 40806267)
13. + Tregs in autoimmunity: learning self-control from experience. Cell Mol Life Sci 68: 3781-3795, 2011.
14. Odyniec A, Szczepanik M, Mycko MP, Stasiolek M, Raine CS and Selmaj KW: γδ-T-cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL-12 production. J Immunol 173: 682-694, 2004. (Pubitemid 38797399)
15. Hayday A and Geng L: γδ-T-cells regulate autoimmunity. Curr Opin Immunol 9: 884-889, 1997.
16. Peng SL, Madaio MP, Hayday AC and Craft J: Propagation and regulation of systemic autoimmunity by γδ-T-cells. J Immunol 157: 5689-5698, 1996. (Pubitemid 126448994)
17. Tsuji S, Char D, Bucy RP, Simonsen M, Chen CH and Cooper MD: γδ-T-cells are secondary participants in acute graft-versus-host reactions initiated by CD4+ αβ-T-cells. Eur J Immunol 26: 420-427, 1996. (Pubitemid 26060251)
18. + and γδ-T-lymphocytes in contact sensitivity. Immunology 93: 469-477, 1998.
19. Sundrud MS and Rao A: New twists of T-cell fate: control of T-cell activation and tolerance by TGF-β and NFAT. Curr Opin Immunol 19: 287-293, 2007. (Pubitemid 46687019)
20. + suppressor T-cells: more questions than answers. Nat Rev Immunol 2: 389-400, 2002.
21. Wood KJ, Sakaguchi S: Regulatory T-cells in transplantation tolerance. Nat Rev Immunol 3: 199-210, 2003.
22. von Herrath MG and Harrison LC: Antigen-induced regulatory T-cells in autoimmunity. Nat Rev Immunol 3: 223-232, 2003.
23. Bach JF: Regulatory T-cells under scrutiny. Nat Rev Immunol 3: 189-198, 2003.
24. + regulatory T- cells. Nat Rev Immunol 11: 119-130, 2011.
25. + T-cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001.
26. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002. (Pubitemid 34921025)
27. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E and Grubeck-Loebenstein B: Increase of regulatory T-cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612, 2003. (Pubitemid 36182591)
28. + regulatory T-cells in patients with gastrointestinal malignancies: possible involvement of regulatory T-cells in disease progression. Cancer 98: 1089-1099, 2003.
29. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR and June CH: Regulatory T cells from lung cancer patients directly inhibit autologous T-cell proliferation. J Immunol 168: 4272-4276, 2002. (Pubitemid 34441324)
30. Nizar S, Meyer B, Galustian C, Kumar D and Dalgleish A: T-regsulatory cells, the evolution of targeted immunotherapy. Biochim Biophys Acta 1806: 7-17, 2010.
31. Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T-cells and immune tolerance. Cell 133: 775-787, 2008.
32. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W: Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004. (Pubitemid 39273735)
33. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E and Marth C: The expression of the regulatory T cell-specific fork-head box transcription factor FOXP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 8326-8331, 2005. (Pubitemid 41746944)
34. + regulatory T-cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434, 2006.
35. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380, 2006. (Pubitemid 46623168)
36. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of regulatory and cytotoxic T-cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593, 2007. (Pubitemid 47041232)
37. + regulatory T-cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93: 193-200, 2008.
38. + regulatory T-cells in patients with gastrointestinal malignancies: possible involvement of regulatory T-cells in disease progression. Cancer 98: 1089-1099, 2003.
39. +/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543, 2005.
40. + cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 59: 653-661, 2010.
41. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, and Vincenti F: The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 8: 2086-96, 2008.
42. Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma 1: S27-31, 2000.
43. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, and Chesney J: Transient T-cell depletion causes regression of melanoma metastases. J Transi Med 6: 1-18, 2008.
44. Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM and Chesney J: Phase II trial of the regulatory T cell-sepleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer In press, 2011.
45. Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ and Pastan I: Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug Chem 4: 112-120, 1993.
46. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA and Pastan I: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18: 1622-1636, 2000. (Pubitemid 30220540)
47. Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA and Pastan I: Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94: 3340-3348, 1999. (Pubitemid 29536127)
48. de Rezende LC, Silva IV, Rangel LB and Guimarães MC: Regulatory T-cell as a target for cancer therapy. Arch Immunol Ther Exp 58: 179-190, 2010.
49. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A and Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-23, 2010.
50. + immunoregulatory T-cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323, 2002.
51. Schaer DA, Murphy JT and Wolchok JD: Modulation of GITR for cancer immunotherapy. Curr Opin Immunol In press, 2012.
52. + regulatory T-cell function. Science 309: 1380-1384, 2005.
53. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J and Sabzevari H: Inhibition of CD4(+)25+ T-regsulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868, 2005. (Pubitemid 40446280)
54. Shibutani S, Inoue F, Aramaki O, Akiyama Y, Matsumoto K, Shimazu M, Kitajima M, Ikeda Y, Shirasugi N and Niimi M: Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 79: 904-913,2005. (Pubitemid 40586862)
55. Kawai M, Kitade H, Mathieu C, Waer M and Pirenne J: Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T-cells in vivo. Transplantation 79: 1073-1077, 2005. (Pubitemid 40664000)
56. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, Zhang Y, Cai Y, Chu Y and Xiong S: Differential impairment of regulatory T-cells rather than effector T-cells by paclitaxel-based chemotherapy. Clin Immunol 129: 219-229, 2008.
57. - tumors. J Immunol 181: 6955-6963, 2008.
58. + regulatory T-cells. Br J Haematol 144: 195-205, 2009.
59. Ohkusu-Tsukada K, Toda M, Udono H, Kawakami Y, Takahashi K: Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy. Eur J Immunol 40: 1011-1021, 2010.
60. + regulatory T-cell homeostasis via hypoxia-inducible factor-1α. Eur J Immunol 38: 2412-2418, 2008.
61. Ou-Yang HF, Zhang HW, Wu CG, Zhang P Zhang J, Li JC, Hou LH, He F, Ti XY, Song LQ, Zhang SZ, Feng L, Qi HW and Han H: Notch signaling regulates the FOXP3 promoter through RBP-J- and HES1-dependent mechanisms. Mol Cell Biochem 320: 109-114, 2009.
62. Sagamura K, Ishii N and Weinberg AD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4: 420-431, 2004. (Pubitemid 38745554)
63. + Treg. Blood 110: 2501-2510, 2007.
64. Piconese S, Valzasina B and Colombo MP: OX40 triggering blocks suppression by regulatory T- cells and facilitates tumor rejection. J Exp Med 205: 825-39, 2008. (Pubitemid 351549881)
65. Mignot G, Roux S, Thery C, Ségura E and Zitvogel L: Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 10: 376-388, 2006. (Pubitemid 44870186)
66. Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux JF, Kobayashi T, Salles JP, Perret B, Bonnerot C and Record M: Mast cell-and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J 380: 161-171, 2004. (Pubitemid 38725741)
67. Ohno H: Overview: membrane traffic in multicellular systems: more than just a housekeeper. J Biochem 139: 941-942, 2006.
68. Wada J, Onishi H, Suzuki H, Yamasaki A, Nagai S, Morisaki T and Katano M: Surface-bound TGF-β1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions. Anticancer Res 30: 3747-3757, 2010.
69. + Tregs. Eur J Immunol 40: 197-203, 2010.
70. Wada J, Yamasaki A, Nagai S, Yanai K, Fuchino K, Kameda C, Tanaka H, Koga K, Nakashima H, Nakamura M, Tanaka M, Katano M and Morisaki T: Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients. Anticancer Res 28: 2401-2408, 2008.
71. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y and Yamaue H: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101: 433-439, 2010.